April 03, 2025

Lung Screening Lags Despite Cancer Prevention Uptake

Eligible patients undergo breast and colorectal cancer screenings at nearly four times the rate of recommended lung cancer screening, revealing significant intervention opportunities, according to a new JAMA study.

Conexiant

April 03, 2025

Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis

A novel machine learning model may outperform standard statistical models in identifying and stratifying allogeneic hematopoietic cell transplantation risk among patients with myelofibrosis.

The ASCO Post

April 02, 2025

HPV Testing Guidelines Updated for Head and Neck Carcinomas

New evidence expands recommendations for sinonasal squamous cell carcinoma and standardizes p16 immunohistochemistry interpretation.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

Active Surveillance vs Standard Surgery After Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

In a Dutch noninferiority phase III trial (SANO) reported in The Lancet Oncology, van der Wilk et al found that active surveillance was noninferior to standard surgery in terms of 2-year overall survi...

The ASCO Post

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Parker Institute for Cancer Immunotherapy Names New CEO

The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO).

The ASCO Post

March 31, 2025

Persistent PSA Associated with Survival Risk

PSA level assessed for at least 3 months postoperatively may minimize overtreatment, according to a recent study.

Conexiant

March 28, 2025

New Dosing Option for Hemophilia A and B

The FDA approved Qfitlia (fitusiran) for hemophilia A or B prophylaxis in patients aged 12 and older, offering reduced bleeding rates with bi-monthly dosing.

Conexiant